Sharekhan

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

What’s Your Call?

Collective community sentiment on Venmax Drugs and Pharmaceuticals Ltd

Your Vote -

Buy

50.00%

Hold

0.00%

Sell

50.00%

50.00%

2 users have voted

No Records Found

Option Chain

Analyzes market sentiment, predicts Venmax Drugs and Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Venmax Drugs & Pharm - Board Meeting Intimation for Allotment Of Equity Shares Pursuant To Conversion Of Convertible Equity S

    8 Aug 2025, 4:52PM Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/08/2025 ,inter alia,
  • Venmax Drugs & Pharm Q1 net profit zooms 300.00% at Rs 0.04 cr

    23 Jul 2025, 5:41PM The company reported standalone net profit of Rs 0.04 crore for the quarter ended June 30, 2025 as compared to Rs 0.01 crore in the same period last y
  • Venmax Drugs & Pharm - Financial Results For The Quarter Ended June 30, 2025.

    23 Jul 2025, 3:42PM Financial Results for the Quarter ended June 30, 2025.
  • Venmax Drugs & Pharm - Board Meeting Outcome for Financial Results For The Quarter Ended June 30, 2025.

    23 Jul 2025, 3:34PM The Board of Directors of the Company have approved the unaudited Financial Results for the Quarter ended June 30th 2025 at their meeting held on July
  • Venmax Drugs & Pharm has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    19 Jul 2025, 12:40PM As of June 2025, 23.13% is owned by Indian Promoters and 76.87% by Public. <p align=justify> Top five Promoters holding highest number of shares of Ve
  • Venmax Drugs & Pharm - Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter Ended June 30,

    16 Jul 2025, 1:42PM Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2025 ,inter alia,
  • Venmax Drugs & Pharm - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    14 Jul 2025, 2:11PM Certificate under Regulation 74(5) of the SEBI (Depositories and Participants Regulations, 2018 for the quarter ended June 30, 2025.

Key fundamentals

Evaluate the intrinsic value of Venmax Drugs and Pharmaceuticals Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 4.4615 -0.298 -0.3624 -0.591 -0.4572
Liabilities 4.4615 -0.298 -0.3624 -0.591 -0.4572
Equity 5.2389 5.2389 5.2389 5.2389 5.2389
Gross Profit -1.0601 -0.1045 -0.1855 -0.1273 -0.3328
Net Profit -0.0105 0.0645 0.2256 1.8462 -0.1624
Cash From Operating Activities -2.2902 0.0022 -0.0031 1.905 0.2638
NPM(%) -1.3 0 0 0 -96.77
Revenue 0.8073 0 0 0 0.1678
Expenses 1.8674 0.1045 0.1855 0.1273 0.5007
ROE(%) 1.58 -9.76 -34.15 -279.49 24.59

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Venmax Drugs and Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 799.95 -0.83 72.61 16.27 301.39 0.62
Lotus Eye Hospital and Institute Ltd 73.85 1.16 210.74 59.27 3.55 0.00
Bharat Immunological and Biologicals Corporation Ltd 21.35 -0.42 0.00 123.06 -39.50 0.00
Astec Lifesciences Ltd 822.00 3.70 0.00 55.89 -601.21 0.00

Company Info

Yenkey Drugs and Pharmaceuticals Ltd., was originally incorporated on 28th September, 1988 in the name of Yenkey Medico Drugs Private Limited. The Company has been converted into a public limited company on 3rd Feb'95 in terms of a special resolution passed on 23.01.95 under Section 31(1)/44 of the Companies Act, 1956. Accordingly the Company has obtained a fresh Certificate of Incorporation consequent on the conversion from the Registrar of Companies, Andhra Pradesh vide ref. no. 01-09102 dated 3rd February, 1995. The Company is producing bulk drug intermediates as detailed above and marketing in the domestic markets. The total turnover of the Company is Rs. 89.70 lacs for the year ended March 1994. Now the Company proposes to expand the existing capacity of dye and drug intermediate viz; ECA and diversifying into manufacturing of high value chemicals and bulk drugs viz; Sodium Azide and Vitamin B2 Phosphate. The Company is also proposing to set up a R & D Unit for maintaining high quality control standards of foreign buyers. 2009 -Company has changed its name from Yenkey Drugs and Pharmaceuticals Ltd. to Venmax Drugs & Pharmaceuticals Ltd. --Registered Office of the Company has been shifted from Plot No. 1-B12, 2nd floor, S.V.Co-operative Industrial Estate, Balanagar, Hyderabad - 500 037 to 8-3-319/3, Behind Sarathi Studio, Yellareddyguda, Hyderabad - 500 073. 2013 -Venmax Drugs and Pharmaceuticals Ltd has informed that Registered office has been shifted from "Plot No-35,Shivbagh Colony, Ameerpet, Hyderabad - 16" TO "H.NO 6-3-349/35, Flat No-21B, Dwaraka Avenue, DwarakaPuri Colony, Punjagutta, Hyderabad - 32". 2023 -Acquired Brownfield Hotel in Varanasi Uttar Pradesh and Aloft Bengaluru Whitefield Hotel in Karnataka. 2024 - Launched Raaya by atmosphere in Maldives. -Completed the Acquistion transaction pursuant to which our company directly/ indlrectly acquired - Aloft ORR Bengaluru, Anantara Maldives and Conrad Maldives.

Yenkey Drugs and Pharmaceuticals Ltd., was originally incorporated on 28th September, 1988 in the name of Yenkey Medico Drugs Private Limited. The Company has been converted into a public limited company on 3rd Feb'95 in terms of a special resolution passed on 23.01.95 under Section 31(1)/44 of the Companies Act, 1956. Accordingly the Company has obtained a fresh Certificate of Incorporation consequent on the conversion from the Registrar of Companies, Andhra Pradesh vide ref. no. 01-09102 dated 3rd February, 1995. The Company is producing bulk drug intermediates as detailed above and marketing in the domestic markets. The total turnover of the Company is Rs. 89.70 lacs for the year ended March 1994. Now the Company proposes to expand the existing capacity of dye and drug intermediate viz; ECA and diversifying into manufacturing of high value chemicals and bulk drugs viz; Sodium Azide and Vitamin B2 Phosphate. The Company is also proposing to set up a R & D Unit for maintaining high quality control standards of foreign buyers. 2009 -Company has changed its name from Yenkey Drugs and Pharmaceuticals Ltd. to Venmax Drugs & Pharmaceuticals Ltd. --Registered Office of the Company has been shifted from Plot No. 1-B12, 2nd floor, S.V.Co-operative Industrial Estate, Balanagar, Hyderabad - 500 037 to 8-3-319/3, Behind Sarathi Studio, Yellareddyguda, Hyderabad - 500 073. 2013 -Venmax Drugs and Pharmaceuticals Ltd has informed that Registered office has been shifted from "Plot No-35,Shivbagh Colony, Ameerpet, Hyderabad - 16" TO "H.NO 6-3-349/35, Flat No-21B, Dwaraka Avenue, DwarakaPuri Colony, Punjagutta, Hyderabad - 32". 2023 -Acquired Brownfield Hotel in Varanasi Uttar Pradesh and Aloft Bengaluru Whitefield Hotel in Karnataka. 2024 - Launched Raaya by atmosphere in Maldives. -Completed the Acquistion transaction pursuant to which our company directly/ indlrectly acquired - Aloft ORR Bengaluru, Anantara Maldives and Conrad Maldives.

Read More

Parent Organisation

Venmax Drugs & Pharmaceuticals Ltd.

Founded

28/09/1988

Managing Director

Mr.N Krishnaiah

NSE Symbol

FAQ

The current price of Venmax Drugs and Pharmaceuticals Ltd is

The 52-week high for Venmax Drugs and Pharmaceuticals Ltd is

The market capitalization of Venmax Drugs and Pharmaceuticals Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Venmax Drugs and Pharmaceuticals Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Venmax Drugs and Pharmaceuticals Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Venmax Drugs and Pharmaceuticals Ltd shares.

The CEO of Venmax Drugs and Pharmaceuticals Ltd is Mr.N Krishnaiah, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT